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a b s t r a c t
Objective: To investigate the quality of life (QOL) following palliative radiotherapy for painful bone
metastases.
Methods: A literature search was conducted in OvidSP Medline (1946–Jan Week 4 2014), Embase (1947–
Week 5 2014), and the Cochrane Central Register of Controlled Trials (Dec 2013) databases. The search
was limited to English. Subject headings and keywords included ‘palliative radiation’, ‘cancer palliative
therapy’, ‘bone metastases’, ‘quality of life’, and ‘pain’. All studies (prospective or retrospective) reporting
change in QOL before and after palliative radiotherapy for painful bone metastases were included.
Results: Eighteen articles were selected from a total of 1730. The most commonly used tool to evaluate
QOL was the Brief Pain Inventory. Seventeen studies collected data prospectively. An improvement in
symptoms and functional interference scores following radiotherapy was observed in all studies. The
difference in changes in QOL between responders and non responders was inconsistently reported.
Conclusion: QOL improves in patients who respond to palliative radiotherapy for painful bone
metastases.
& 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Bone is one of the most common sites of metastasis in advanced
cancer, present in approximately 50–75% of patients [1]. Bone
metastases are especially prevalent in patients with prostate, breast,
or lung primaries [2–4] and are of great concern to both physicians
and patients as they can result in complications such as pathologic
fractures, hypercalcemia, and spinal cord compression [2,5–7]. One
of the most common symptoms of bone metastases is pain,
occurring in an estimated 70% of patients [8]. Often, patients
initially present with multiple bone metastases and often, multiple
sites of pain. Pain may be localized or diffuse, and may worsen upon
weight bearing [9]. As a consequence of bone pain, patients often
have increased difﬁculty with activities of daily living and decreased
quality of life (QOL) [8].
Radiation therapy (RT) is considered to be the standard treat-
ment for cancer patients with symptomatic bone metastases
[3,7,10,11]. Various studies have shown that approximately
60–70% of patients experience at least some degree of pain relief
following RT, regardless of radiotherapy regime [5,7]. Moreover,
about 25% of patients experience complete pain relief, otherwise
known as a complete response [2,7]. Although pain relief is a
proven beneﬁt of radiation therapy, this is not necessarily indica-
tive of improved QOL.
QOL is a multidimensional model that attempts to capture the
physical, social, and psychological well-being of the patient [12].
Many components inﬂuence QOL, including physical symptoms of
the disease, side effects of treatment, social and family support.
Treatment in the advanced cancer population is palliative rather
than curative in intent, meaning that the goal is managing
symptoms as opposed to prolonging life [7,13]. With this goal in
mind, it is important for health care providers to consider treat-
ment in terms of not only managing symptoms, but also stabilizing
or improving other factors that affect QOL.
As QOL is a subjective concept, it can be difﬁcult to capture in
an accurate and meaningful fashion [12]. Currently, various tools
are employed to assess pain and QOL in advanced cancer patients
and in those speciﬁcally with bone metastases. The European
Organisation for Research and Treatment of Cancer (EORTC) has
developed one of the most commonly used measurements for this
purpose: the QLQ-C30 [13]. Associated with this measurement is
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/jbo
Journal of Bone Oncology
http://dx.doi.org/10.1016/j.jbo.2014.11.001
2212-1374 & 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
n Correspondence to: Department of Radiation Oncology, Odette Cancer Centre,
Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada
M4N 3M5. Tel.: þ1 416 480 4806; fax: þ1 416 480 6002.
E-mail address: May.Tsao@sunnybrook.ca (M. Tsao).
Journal of Bone Oncology 4 (2015) 24–31
the QLQ-C15-PAL, a reduced version of the parent QLQ-C30
designed to capture QOL outcomes in a brief internationally
recognized and validated tool. The EORTC QLQ-BM22 is a sub-
module of the QLQ-C30 and is an internationally recognized
and validated scale used to measure QOL in bone metastases
patients [7,12].
Another widely used tool is the Brief Pain Inventory (BPI),
developed by Cleeland and Ryan. The BPI is a questionnaire used
to determine overall pain intensity and functional interference as a
result of pain. Speciﬁcally, it examines functional interference in
terms of general activity, normal work, walking ability, mood,
sleep, relations with others, and enjoyment of life [6]. In addition,
it captures three aspects of pain: worst, average, and current
intensity.
Finally, the Edmonton Symptom Assessment System (ESAS)
examines symptoms on a scale of 0, representing ‘absence of
symptom’ to 10, representing ‘worst possible symptom’ [14].
Symptoms captured in this questionnaire are pain, tiredness,
nausea, depression, anxiety, drowsiness, appetite, feeling of well-
being, and shortness of breath. In general, symptoms given a
rating of 1–3 are considered mild, 4–7 are considered moderate,
and 8–10 are considered severe [14].
The objective of this review was to investigate changes in QOL
following RT for painful bone metastases. Speciﬁcally, we wanted
to determine whether or not those who experienced pain relief
post-treatment also experienced a positive response in QOL
compared to non responders.
2. Methods
A literature search was conducted using OvidSP Medline
(1946–Week 4 2014), Embase (1947–Week 5 2014), and the
Cochrane Central Register of Controlled Trials (Dec 2013) data-
bases. The search was limited to English. Subject headings and
keywords utilized for the search included ‘palliative radiation’,
‘cancer palliative therapy’, ‘bone metastases’, ‘quality of life’, and
‘pain’.
Any publication which reported change in QOL using a vali-
dated scale following RT was included in this review. Exclusion
criteria were literature reviews and articles that discussed QOL
solely before radiation treatment, as well as those which only
discussed pain. Titles and abstracts of articles generated in the
initial search were independently screened by RM and GB and
potential articles were identiﬁed. Articles were then retrieved and
examined further for relevancy.
3. Results
The literature search resulted in a total of 1730 articles.
Eighteen of these articles, published between 1977 and 2013,
met the eligibility criteria [1,3,4,7,8,11–22]. All studies collected
data prospectively, except for that by Gilbert et al. [20] who
determined QOL through chart review. Only 3 of the studies were
randomized control trials [3,21,22], while the rest employed no
other intervention than the questionnaire.
The most commonly used tool was the BPI, used in a total of six
papers [1,4,10,11,15,16]. The next most commonly used assess-
ment tools were EORTC measures and the ESAS, which were
employed in ﬁve [7,12,13,18,19] and three [8,14,17] studies,
respectively. Other assessment tools included the Patient-
Generated Subjective Global Assessment, net pain relief, the
McGill–Melzalk Score, the Spitzer scale, and others [3,20–22]. In
total, eight articles [1,4,7,10,12,15,16,18] directly compared QOL in
responders and non-responders, as deﬁned by the International
Bone Metastases Consensus guidelines, while the remaining ten
[3,8,11,13,14,17,19–22] made no differentiation between the two
patient groups.
3.1. Brief Pain Inventory
All of the six articles that utilized the BPI reported at least some
improvement in functional interference at one month following
radiotherapy for painful bone metastases (Table 1). However, the
speciﬁc functional items, the degree to which they improved, and
whether the improvement was observed in only responders were
inconsistently reported among the publications.
Wu et al. [11] published their study in 2006, which investigated
pain relief and QOL following RT for patients with bone metas-
tases. These authors reported that there was an improvement in
all seven functional items of the BPI one month following treat-
ment; however they did not differentiate between responders and
non responders [11]. Nguyen et al. [1] and Hadi et al. [4] also
observed an improvement in all functional interference scores
post-treatment. It was reported by Nguyen et al. [1] that
only mood was signiﬁcantly related to responders, whereas Hadi
et al. [4] concluded that all items except mood, relations with
others, and sleep, were signiﬁcantly related to pain response.
Harris et al. [15] found a signiﬁcant reduction in interference with
general activity, normal work, enjoyment of life, and average
functional interference in responders. No signiﬁcant reduction
was found for any functional interference scores in patients
classiﬁed as non responders.
Zeng et al. [10] observed that improvement in all functional
interference scores was signiﬁcantly related to responders, except
for sleeping problems at month two and four post treatment. In
contrast, Khan et al. [16] reported an improvement in sleep at two
and three months post RT in responders. In non responders, sleep
was reported to have improved at month one and two, but then
worsened at month three.
3.2. Edmonton Symptom Assessment Scale
The ESAS was used in three of the 17 included studies, none of
which differentiated between responders and non responders.
Both Pituskin et al. [8] and Fairchild et al. [14] concluded similar
pain response post-treatment, with pain scores decreasing from
6.1/10 and 6.08/10 at baseline, to 2.6/10 and 2.96/10 post-treat-
ment, respectively. In terms of symptoms, Pituskin et al. [8]
reported that shortness of breath, nausea, and appetite were the
only symptoms that did not show signiﬁcant improvement at a
four week follow-up. Contrastingly, Fairchild et al. [14] found
improvement in all symptom severities at weeks one and four
post treatment, although improvement was reported as the
percentage of patients who experienced symptom relief, with no
mention of the statistical signiﬁcance when compared to baseline.
Chow et al. [17] also utilized the ESAS with a large population
of 518 patients. These authors assessed pain and QOL at 1, 2, 4, 8,
and 12 weeks post RT and observed an improvement in global
pain, index pain, anxiety, and sense of well-being for all patients
throughout the follow-up. All articles that employed the ESAS to
measure QOL can be found in Table 2.
3.3. European Organization for Research and Treatment of Cancer
quality of life questionnaires
A total of ﬁve studies used EORTC developed questionnaires;
three used the QLQ-C30, one used the QLQ-C15-PAL, and one used
both the QLQ-BM22 as well as the QLQ-C30 (Table 3). Miszczyk
et al. [13] used the QLQ-C30 when evaluating patients who were
treated with half-body irradiation for symptomatic bone
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Table 1




Population and time of accrual Questionnaire administration Responders Non-responders Ref
Wu et al.
(2006)
July 2002–July 2005 Baseline and 4–6 weeks post treatment Overall pain response of 72% NA [11]
All patients treated with
palliative radiation for bone
metastases
Signiﬁcant reduction for all 7 functional
interference
items after treatment with greatest improvement
seen in general activityN¼109
Harris et al.
(2007)
May 2003–June 2005 Baseline and 2 months post treatment Signiﬁcant decrease in functional interference
scores
in general activity, normal work, enjoyment of life,
and
average functional interference
No signiﬁcant difference in functional
interference scores
[15]
All patients treated with palliative radiation for bone
metastases
Pain progression in 11%, 14%, and
13% (worst, average, current pain
scores)
N¼199 Overall response in 66%, 58%, and 54% for worst,
average,
and current pain scores, respectively
No change in pain for 23%, 28%, and




May 2003–Jan 2007 Baseline and Months 1, 2, and 3 post treatment All symptom severities improved over time NA [4]
All patients treated with palliative
radiation for bone metastases
All symptoms except for mood, relations with
others,
and sleep were related to responders
N¼348 Response rates of 56.5%, 57.5%, and 66.7%
at weeks 4, 8, and 12 respectively
Nguyen et al.
(2011)
May 2003–June 2005 Baseline and Months 1, 2, and 3 post treatment All pain scores and functional interference scores
improved over time
All BPI scores were signiﬁcantly
improved
following RT except for mood
[1]
All patients treated for spinal metastases Mood was the only signiﬁcant BPI functional item
signiﬁcantly related to respondersN¼109
Khan et al.
(2011)
May 2003–June 2007 Baseline and months 1, 2, and 3 post treatment Improvement in sleep at week 4, 8, and 12 Improvement in sleep at weeks 4 and
8, worsened at week 12
[16]





May 2003–June 2007 Baseline and each month for 6 months post
treatment
Improvement in pain and functional interference
scores signiﬁcantly related to responders, regardless
of spine or non-spinal location, except for sleeping
problems at month 2 and 4
NA [10]



















metastases. Not only did pain decrease from 6.1 at baseline to
3.1 two weeks post-treatment, but all ﬁve functional scales
(physical functioning, role functioning, emotional functioning,
cognitive functioning, and social functioning) also demonstrated
improvement over time. The same held true for global QOL, and all
symptom scales except for diarrhea and ﬁnancial difﬁculties [13].
Another study, conducted by Lee et al. [18] investigated pain
relief and QOL in patients with metastatic renal cell carcinoma.
Although this study did not focus solely on bone metastases in
these patients, 25 of a total of 31 patients were radiated for painful
bone metastases. Improvement in QOL was reported by 33% of
patients, no signiﬁcant change by 21%, and decline in QOL by 46%.
Physical functioning was reported as improved in 48% of patients
and symptom improvement in 22% of patients [18].
A study conducted by Lam et al. [19] used the QLQ-C30 and
reported improvement in physical and emotional functioning,
global health score, pain, insomnia, constipation, and ﬁnancial
problems following RT. No differentiation between responders and
non responders was made [19].
The QLQ-BM22, in conjunction with the QLQ-C30, was used in a
study conducted by Zeng et al. [7]. Fifty-nine patients had
complete follow-up data of which 22, 8, and 29 experienced a
partial response, pain progression, and an indeterminate response,
respectively. Lower scores for painful sites, painful characteristics,
and pain were seen at follow-up for responders when compared to
non-responders. Responders also experienced improved physical
and role functioning, as well as functional interference and
constipation. Improvement, although not signiﬁcant, was seen in
psychosocial aspects and global health status in responders
compared to non responders [7].
Caissie et al. [12] used the QLQ-C15-PAL in their study of 178
patients with symptomatic bone metastases. Overall radiotherapy
response was seen in 45% of patients at week 1, 62% at week two
and month 1, and 65% at month 2. In responders, overall QOL
signiﬁcantly improved two months post radiation therapy.
Furthermore, improvement was also seen in emotional function-
ing, fatigue, insomnia, constipation, and pain. Contrastingly, no
improvement was seen in overall QOL, functioning, or symptoms
in non responders [12].
3.4. Other pain and quality of life assessments
A variety of other pain assessments were used in studies
published between 1977 and 2001 (Table 4). Gilbert et al. [20]
used Karnofsky Performance Status (KPS), which measures func-
tional impairment, to assess QOL. Patients who spent most of their
life being able to care for most of their own needs were considered
to have “good” QOL, deﬁned as Level 1. Those with difﬁculty
ambulating and extreme skeletal pain were categorized as Level 2.
Of 120 total patients, 63% experienced “good” QOL post-treatment,
although the prevalence of such was not reported before treat-
ment [20].
Gaze et al. [3] investigated symptoms and QOL using Eastern
Hospital Anxiety and Depression (HAD) scale and Spitzer's QOL
Index. Spitzer's QOL Index is a ﬁve item questionnaire about
activity, daily living, health, support, and outlook. Using these
tools, Gaze et al. [3] reported a decreased prevalence of anxiety
and depression and improved QOL in responders for both fractio-
nation schedules.
Nielsen et al. [21] assessed pain relief and QOL through a 5 point
visual analog scale that included pain, global QOL, and analgesic
consumption. Similarly to Gaze et al. [3], they reported an increase
in QOL regardless of fractionation schedule, with a total of 7% of
patients experiencing a complete feeling of well-being.
A randomized trial was conducted by Salazar et al [22] in 2001 in
which patients were randomized to receive 15 Gy in 5 fractions in
5 days, 8 Gy in 2 fractions in 1 day, or 12 Gy in 4 fractions in 2 days.
The authors found an improvement in QOL in patients with the ﬁrst
and third radiation schedule, but signiﬁcantly worse QOL in patients
randomized to the second schedule. This was consistent for all
primaries except prostate, in which the ﬁrst protracted schedule (15
Gy in 5 fractions in 5 days) was favoured.
4. Discussion
As a multidimensional concept that encompasses the well-
being of the whole person, QOL is both difﬁcult to deﬁne and
measure. Often, bone metastases cause pain which decreases
mobility and interferes with physical functioning. In turn, this
may lead to an inability to seek support from friends and family,
causing emotional and psychological distress. In an article written
by Carlson et al. [23], distress was deﬁned as “normal feelings of
vulnerability, sadness, and fears, to problems that can become
disabling such as depression, anxiety, panic, social isolation, and
spiritual crisis”. These authors stated that distress is associated
with reduced survival and QOL, and that both pain and fatigue are
highly validated components of distress. This was further con-
ﬁrmed in a study conducted by Kaasa et al. [24], who showed that
psychological distress is related to pain and reduced performance
status.
Currently, treatment response is deﬁned by the International
Bone Metastases Consensus guidelines in terms of pain score
and analgesic consumption [25]. It is hypothesized that, if
Table 2
A summary of articles that employed the Edmonton Symptom Assessment Scale (ESAS) to measure QOL.





Chow et al. (2004) Jan 1999–Jan 2002 Baseline, and 1, 2, 4, 8,
12 weeks post treatment
Improvements in global pain, index pain, anxiety,
and sense of well-being for all patients
NA [17]
All patients treated with palliative
radiation for bone metastases
N¼518
Pituskin et al. (2009) Jan 2007–Dec 2007 Baseline and 1 month Improvement in mean follow-up pain score,
all symptoms except for shortness of breath,
nausea, and appetite signiﬁcantly
improved by 4 weeks
NA [8]
All patients treated with palliative
radiation for bone metastases
N¼82a
Fairchild et al. (2009) Aug–Dec 2006 Baseline and week 1 and
4 post treatment
Improvement or stabilization in nausea (93%),
anxiety (91%), depression (87%), fatigue (81%),
drowsiness (81%), shortness of breath (81%),
well-being (78%), and appetite (77%)
NA [14]
Patients treated with palliative
radiation for bone metastases
N¼31
a Patient-Generated Subjective Global Assessment (PG-SGA) was also utilized.
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Table 3
A summary of articles using European Organization for Research and Treatment of Cancer (EORTC) measurements to assess QOL.
Article authors
(year)
Population and time of accrual Assessment tool Questionnaire administration Responders Non-responders Ref
Lee et al. (2005) 1996–2002 EORTC QLQ-C30
and McGill-
Melzack score
Baseline, Months 1 and 3 post
treatment, and every 3 months for one
year post treatment
83% had a decrease in site-speciﬁc pain No signiﬁcant change in
quality of life in 21%
[18]
Patients with metastatic renal cell
carcinoma, N¼31
33% reported increase in quality of life by 2 months Worsening in global quality
of life at 1 month by 46% of
patientsPatients with metastatic renal cell
carcinoma being treated for symptomatic
bone metastases, N¼25
Increase in physical functioning measured by EORTC
QLQ-C30 in 48% of patients
Miszczyk et al.
(2008)
May 2001–Sept 2006 EORTC QLQ-C30 Baseline, week 2, week 4, and every
month post treatment until death or too
ill to respond
Decrease in use of strong opioids NA [13]
All patients with bone metastases treated
with single half-body irradiation
Increase in those who do not need analgesics
N¼95
Signiﬁcant increase in physical, role, emotional, and
social functioning after treatment
Improvement in global quality of life




Oct 2007–July 2010 QLQ-C15-PAL Baseline, week 1, week 2, month 1 and
month 2 post treatment






Patients treated with palliative radiation for
bone metastases
Signiﬁcant increase in quality of life by month 2
N¼178 Pain score improved to 2.6/10
Zeng et al. (2012) Mar 2010–Jan 2011 QLQ-BM22, QLQ-
C30
Baseline and month 1 post treatment By month 1 follow-up, improvement in three of four QLQ-
BM22 domains (painful site, painful characteristic,
functional interference) and 3 QLQ-C30 domains (physical









Psychosocial aspects and global health status improved
Lam et al. (2013) Mar 2010–Jan 2011 QLQ-C30 Baseline and 1 month follow-up Improvement in physical functioning, emotional
functioning, global health score, pain, insomnia,
constipation, and ﬁnancial stressors
NA [19]




















A summary of articles using assessment tools other than the Brief Pain Inventory, Edmonton Symptom Assessment Scale, or European Organization for Research and Treatment of Cancer measurements.
Article authors
(year)
Population and time of accrual Assessment Tool Questionnaire
Administration
Responders Ref
Gilbert et al. (1977) 1970–1973 Level 1 – Ability to care for most personal needs Baseline and once
every three months
for one year or until
death
74% achieved local pain free at 3 months [20]
Patients treated with radiation for bone metastases QOL considered “good” in 63%, meaning they were
relatively pain free, could ambulateN¼158 Level 2 – Require major help in self-care
Gaze et al. (1997) Feb 1988–May 1993 Hospital Anxiety and Depression, Spitzer's QOL Index Baseline, week 1,
weeks 3–4, and
every 2 months post
treatment
Prevalence of anxiety and depression decreased for
both schedules
[3]
Patients treated with radiation for painful bone metastases,
comparing a single 10 Gy treatment or 22.5 Gy/5 Quality of life improved for both schedules
N¼200 and 209 for Hospital Anxiety and Depression
Questionnaire and Spitzer's Index, respectively
Nielsen et al. (1998) Jan 1989–Dec 1994 Visual Analog Scale (VAS) and 5 point categorical pain
scale, global QOL, and analgesic consumption
Baseline, and weeks
4, 8, 12, and 20 post
treatment
At 4 weeks post treatment, similar improvement in
VAS QOL seen in patients in both treatment arms with
20Gy/4
[21]
Patients treated with radiation therapy for painful bone
metastases randomized to be treated with 8 Gy/1 or
20 Gy/4
N¼241
Salazar et al. (2001) Mar 1996–Jan 31, 1999 Net pain relief as designed by RTOG (divide pain free
survival time by overall survival, then multiple by
100%¼ remaining life % spent pain free without
retreatment)
Undeﬁned 91% achieved some response, 45% achieved complete
response
[22]
Patients treated with half-body radiation for painful bone
metastases, randomized to receive 15Gy in 5 fractions in 5
days, 8Gy in 2 fractions in 1 day, and 12Gy in 4 fractions in 2
days
QOL assessed using net pain relief concept
Average net pain relief¼ 71%
N¼156
Improvement in initial performance status and
narcotic use, and as a result, improvement in QOL


















psychological distress is related to pain and reduced performance
status, an improvement in pain will lead to an improvement in
psychological aspects of one's health and QOL. Our literature
review conﬁrmed that the majority of patients experience an
improvement in QOL following RT; however, it is unknown which
aspects of QOL improve, and the degree to which this improve-
ment is related to pain response.
Part of the difﬁculty in determining which aspects of QOL
improve is due to the wide range of questionnaires used. Although
there has been an effort to standardize assessment tools in recent
years, for example with the development of the QLQ C15-PAL and
the BM22, there still remains an inconsistent approach to asses-
sing QOL. This makes it difﬁcult to compare the individual
functional interference items and symptom scales between ques-
tionnaires. Future studies are required to determine the most valid
and reliable QOL questionnaire. This questionnaire should then be
employed in a large prospective study investigating the possible
existence of a positive correlation between pain relief and
improvement in QOL following palliative radiotherapy for painful
bone metastases.
Only three of the 18 studies were randomized control trials
[3,21,22], all of which were exploring the use of fractionation
schedule and radiation technique. Numerous other randomized
control trials have investigated similar questions; however their
primary endpoints are often pain score, survival, and toxicity. It is
important for the endpoints of these randomized control trials to
be reconsidered to include QOL because its maintenance or
improvement is such a vital goal of palliative treatment.
4.1. Limitations
In studies investigating variables in a palliative cancer popula-
tion, patient attrition is always one of the main limitations. This is
a limitation in all studies included in this review, as all studies
involved post-radiation follow-up at which point patients could
either have died or become no longer contactable. In addition, only
patients who were well enough to complete follow-up question-
naires were included in follow-up data. As such, those who have a
poorer QOL and physical functioning may not be able to provide
data. Results may overestimate an improvement in QOL as a result.
These studies are also limited in that they do not exclude those
who are on other cancer treatments, including hormone therapy
and chemotherapy. These anti cancer therapies are associated with
side effects which may impact QOL. Therefore, the accuracy of
reported changes in QOL is confounded by these treatments.
Finally, it is noted that a variety of follow-up schedules were
used across the studies included in this review. Evidently, the
optimal duration of time to follow these patients is unknown.
Future studies would be useful in determining an appropriate
period of follow-up, in order to ensure that trial endpoints can be
reached without placing too much burden on patients.
5. Conclusion
Overall, despite somewhat contradicting results and limited
literature, it seems that there may be at least some improvement
or stabilization in QOL in patients who respond to radiation
therapy. This, combined with the knowledge that 60–70% of
patients experience pain relief post-treatment, satisﬁes the goals
of palliative treatment: to manage symptoms and improve or
stabilize QOL. Future studies using a validated questionnaire that
look at a correlation between responders to RT and improvement
in QOL would be useful in determining the degree to which QOL
can be expected to improve following treatment. This would be
useful to allow informed decision making for both patients and
physicians, especially when offering treatment to patients with
lower performance status and poorer prognosis.
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